Press Releases CorMedix Inc.

Stocks

CRMD

US21900C3088

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 15/07/2026 am IST			5-day change	1st Jan Change
8.270 ^USD	-0.60%		-6.76%	-28.89%

07/07	RBC Capital Trims CorMedix Price Target to $13 From $14, Maintains Outperform Rating	MT
03/07	CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer	MT

Press Releases

08/06	U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation	AQ
15/05	Cormedix Therapeutics to Participate in two Upcoming Investor Conferences	AQ
14/05	CorMedix: Q1 Earnings Snapshot	AQ
14/05	Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05/05	CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026	AQ
27/04	CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients	AQ
07/04	CorMedix to Participate in Needham Virtual Healthcare Conference	AQ
05/03	CorMedix: Q4 Earnings Snapshot	AQ
05/03	CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
02/03	CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026	AQ
12/02	CorMedix to Participate in Upcoming Investor Conferences	AQ
02/02	CorMedix Therapeutics Announces Share Repurchase Program	AQ
29/01	CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026	AQ
09/01	CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
08/01	CorMedix Therapeutics Announces Leadership and Board Updates	AQ
08/01	CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates	AQ
18/12	CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath	AQ
13/11	Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update	PR
12/11	CorMedix: Q3 Earnings Snapshot	AQ
12/11	CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance	AQ
31/25/31	CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025	AQ
23/25/23	CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath	AQ
21/25/21	Talphera Announces the Appointment of Joe Todisco to Board of Directors	PR
20/25/20	CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance	AQ
29/25/29	CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO	AQ